ERBB2-altered NSCLC tumors with high PD-L1 expression are infrequent and typically have low TMB (10, 16), but evidence suggests the clinical characteristics, genomic landscape of co-mutations, response to TKIs, and associations with ICI predictive biomarkers are distinctly different among NSCLC tumors with ERBB2 mutations versus amplifications (61–63). This evidence concerns the gene CD274 and non-small cell lung carcinoma.